Efficacy of NovoSeven® during surgery on a haemophiliac with previous history of inhibitors

Haemophilia

Volumn 9, Issue 1, 2003, Pages 131-136

  Saba, H I ^a,b,c   Morelli, G A ^a,b   Azam, R R ^a,b   Klein, C J ^c   Letson, G D ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Factor inhibitor; Factor VIIa; Haemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BLEEDING; CASE REPORT; CONCENTRATION (PARAMETERS); DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; HEMOPHILIA A; HUMAN; JOINT PROSTHESIS; LABORATORY TEST; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SHOULDER; SHOULDER DISLOCATION; ARTHROPLASTY; DRUG ANTAGONISM; HEMOSTASIS; METHODOLOGY;

ADULT; ARTHROPLASTY, REPLACEMENT; FACTOR VII; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS, SURGICAL; HUMANS; MALE; RECOMBINANT PROTEINS; SHOULDER DISLOCATION;

EID: 0037273580     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00693.x     Document Type: Article

References (30)

1. Ehrenforh S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
2. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5: 11-17.
3. Abildgaard CF, Penner JA, Watson-Williams EJ. Anti-inhibitor coagulant complex (Autoplex) for treatment of factor VIII inhibitors in hemophilia. Blood 1980; 56: 978-84.
4. Lusher JM. Recombinant Factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26 (Suppl. 1): 124-30.
5. Shapiro A. Inhibitor treatment: State of the art. Semin Hematol 2001; 38 (Suppl. 12): 26-34.
6. Brinkhous KM, Hedner U, Garris JB, Diness B, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand Disease. Proc Natl Acad Sci USA 1989; 86: 1382-6.
7. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA Gastineau DA. Prospective, randomized trial of two doses of rFVIIa (NovoSeven®) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
8. Ingerslev J, Freidman D, Gastineau D et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996; 26 (Suppl. 1): 118-23.
9. Scharrer I. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 1999; 5: 253-9.
10. Leibman HA, Chediak J, Fink KI, Galvez AG, Shah PC, Sham RL. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000; 63: 109-13.
11. Wong WY, Huang WC, Miller R, McGinty K, Whisnant JK. Clinical efficacy and recovery levels of recombinant FVIIa (NovoSeven) in the treatment of intracranial haemorrhage in severe neonatal FVII deficiency. Haemophilia 2000; 6: 50-4.
12. Schmidt ML, Smith HE, Gamerman S, DiMichele D, Glazer S, Scott JP. Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor. Br J Haematol 1991; 78 (3): 460-3.
13. Papadaki HA, Xylouri I, Valatas W, Petinarakis J, Kontopoulou I, Eliopoulos GD. Severe acquired hemophilia A successfully treated with activated recombinant human factor VII. Ann Hemat 1998; 77: 123-5.
14. Shafi T, Jeha MT, Black L, Al Douri M. Severe acquired hemophilia A treated with recombinant factor VIIa. Br J Haematol 1997; 98: 910-2.
15. Muleo G, Santoro R, Iannaccaro PG, et al. Small doses of recombinant factor VIIa in acquired deficiencies of vitamin K dependent factors. Blood Coagul Fibrinolysis 1999; 10: 521-2.
16. Friederich PW, Wever PC, Briet E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66: 292-4.
17. Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with Type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000; 83 (4): 633-4.
18. Majumdar G, Phillips JK, Lavallee H, Savidge GF. Acquired haemophilia in association with Type III von Willebrand's disease: successful treatment with high purity von Willebrand's factor and recombinant factor VIIa. Blood Coagul Fibrinolysis 1993; 4: 1035-7.
19. D'Oiron R, Ménart C, Trzeciak MC et al. Use of recombinant factor VIIa in 3 patients with inherited Type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost 2000; 83: 644-7.
20. Ancliff P, Liesner R, Khair K, Hann I. The use of recombinant factor VIIa in a patient with severe Glanzmann's thrombasthenia to facilitate insertion of a Port-a-Cath. Blood Coagul Fibrinolysis 1999; 10: 447-8.
21. Tengborn L, Petruson B. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa. Thromb Haemost 1996; 75 (6): 981-82.
22. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost 1998; 80 (2): 352.
23. Fishman RHB. FVIIa used in critically wounded. Lancet 1999; 354: 133.
24. Kenet G, Waldren R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
25. Macik BG. Treatment of factor VIII inhibitors: products and strategies. Semin Thromb Hemost 1993; 19: 13-24.
26. Lusher JM. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors - benefits and limitations. Semin Hematol 1994; 31: 49-52.
27. Brettler DB, Forsberg AD, Levine PH et al. on behalf of the Cooperating Investigators. The use of porcine factor VIII concentrate (Hyate: C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med 1989; 149: 1381-5.
28. Hay CR, Lozier JN, Lee CA et al. Porcine factor VIII in patients with congenital hemophilia and inhibitors: efficacy, patient selection and side effects. Semin Hematol 1994; 31: 20-5.
29. Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-91.
30. Tagariello G, De Biasi E, Gajo GB, et al. Recombinant FVIIa (NovoSeven®) continuous infusion and total hip replacement in patients with haemophilia and high titer of inhibitors to FVIII: experience of two cases. Haemophilia 2000; 6 (5): 581-3.